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Abstract
Multi-parametric magnetic resonance imaging is
increasingly being recommended as standard imaging
modality for prostate cancer diagnosis and staging. It
comprises structural T2 and T1 sequences supplemented
by functional imaging techniques, i.e. diffusion-
weighted, dynamic contrast enhanced and spectroscopic
imaging. Pre-biopsy multi-parametric magnetic
resonance imaging is recommended for both detection
and staging as it avoids biopsy artefact, and when
normal, has a negative predictive value of 95% for
significant cancer. Magnetic resonance imaging-guided
prostate biopsy targets only area(s) considered to be
suspicious for prostate cancer, hence resulting in
improved accuracy. Dynamic contrast enhancing helps in
the detection of cancer and for the assessment of extra-
capsular extension, distal urethral sphincter and seminal
vesicles involvement. The role of multi-parametric
magnetic resonance imaging in follow-up of patients on
active surveillance is also increasingly recognised. Its role
is now further expanded to facilitate targeted therapies.
This review focuses on the evolving role of multi-
parametric magnetic resonance imaging in diagnosis
and management of prostate cancer.
Keywords: Magnetic resonance imaging, Prostate,
Cancer, Multi-parametric.
Introduction
Prostate cancer is one of the most common cancers and
leading causes of death in industrialised nations.1,2 The
classical diagnostic tools for detecting prostate cancer
are prostate specific antigen (PSA), digital rectal
examination (DRE) and trans-rectal ultrasound (TRUS)-
guided biopsy. Imaging has a pivotal part in prostate
cancer treatment selection and planning.3 In the recent
years, magnetic resonance imaging (MRI) has taken up a
greater role in the diagnostic algorithm of prostate
cancer.
MRI equipment and technical considerations
Compared with the conventional MRI using phased- array
coil, combining the endo-rectal coil provides state-of-the-
art imaging for staging prostate cancer with excellent
signal quality and improved spatial resolution.3,4 Higher
magnetic fields at 3-Tesla provides a twofold increase in
signal-to-noise ratio (SNR), shorter overall scan time and
increase in spatial, temporal and spectroscopic resolution
with better structural and functional detail compared to
low field strength (e.g. 1.5 T) MRI.5
Multi-parametric (mp) MRI
Multi-parametric MRI (mp-MRI) includes combination of
high-resolution T2-weighted images assessing the
anatomy and at least two functional MRI techniques, i.e.
diffusion weighted imaging (DWI) and magnetic
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Table: Different components of multi-parametric (mp) MRI.
Modality                              Principle                                      Clinical utility
MRI: Magnetic resonance imaging
T1W: T1-weighted

























Primary sequence of visualization of
structures in and out of the gland.
Best depiction of prostate zonal anatomy
(Detection, localization and staging of
prostate cancer). 
Cancer is low in signal.
Sensitive but not specific for prostate cancer. 
Detection of prostate cancer foci 
Rapid cell turnover with reduced
extracellular space
Low signal intensity on ADC (apparent
diffusion coefficient) maps.
Discriminatory power to distinguish b/w
high vs. low Gleason grade disease
Adds specificity and lesion
characterization.
Uses T1W sequences
Differentiates carcinomatous foci from
BPH nodules.
Expressed by enhancement pattern i.e.
early enhancement and early washout
Adds sensitivity for cancer detection
Detect malignancy in peripheral zone.
Increased choline/ citrate ratio
Adds specificity and lesion
characterization. 
resonance spectroscopic imaging (MRSI), adding
specificity and lesion characterisation.6 Perfusion-based
dynamic contrast-enhanced MRI (DCE-MRI) has high
sensitivity in cancer detection6 (Table). De Rooij M. et al. in
a meta-analysis found mp-MRI to have high specificity,
negative predictive value (NPV) and sensitivity for
detecting prostate cancer.7
Morphological / Anatomical information
The detection of prostate cancer depends upon the type
of image sequence used. Higher resolution T2-weighted
(T2W) MRI imaging offers best information about
prostatic capsule and zonal anatomy, hence used for
detection, localisation and staging of prostate cancer7
(Figure-1).
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T1W: T1-weighted. T2W: T2-weighted
Figure-1: Normal Prostate; a) T1W image-prostate gland is iso-intense to the surrounding muscles. b) T2W image- Prostate gland is slightly hyper-intense to the surrounding muscles
especially the peripheral zone.
T1W: T1-weighted. T2W: T2-weighted. FATSAT: Fat saturation
Figure-2: Tumour nodule. a) FATSAT -T1W image shows an iso-intense nodule at the right lateral zone of the prostate gland which is difficult to differentiate from the normal prostate
gland due to similar signal intensity, but appears as an asymmetrical bulge. b) T2W image; re-demonstration of an iso-intense nodule in the right lateral aspect of the prostate gland.
This is relatively hyper-intense to the surrounding muscles but is still hypo-intense to the peripheral zone.
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T1W: T1-weighted. T2W: T2-weighted
Figure-3: a) T1W image of the prostate shows a nodule occupying the left half of the prostate gland. As this is iso- intense to the prostate gland, therefore, difficult to appreciate on
T1W images. A tiny hyper-instense focus at the right lateral aspect of the prostate represents hemorrhage due to recent biopsy. b) T2W image show the nodule in left lateral aspect of
the prostate gland which is slightly hyper-intense to the surrounding muscles but is still hypo-intense to the normal prostate gland.
MR: Magnetic resonance.
Figure-4: a) Diffusion weighted image (DWI) show a hyper intense focus corresponding to the nodule seen in the right lateral zone of prostate gland. (1.5 Tesla MR images). b)
Apparent diffusion coefficient (ADC) map show a corresponding low intensity focus in the right lateral zone of prostate gland. The hyper-intense signal on DWI and corresponding hypo-
intensity on ADC map represent diffusion restriction. (1.5 Tesla MR images).
The classical MR appearance of prostate cancer is a round
or ill defined, low signal intensity focus (hypo-intense) in
the background of bright peripheral zone tissue. This is
due to loss of normal glandular (ductal) morphology in
prostate cancer6 (Figure-2). 
On T1-weighted images, the tumour is almost
impossible to detect because of homogenous medium
signal intensity with difficulty discerning the zonal
anatomy.4,8 This sequence, however, is useful to detect
the post biopsy haemorrhage, which appears as areas
of high T1 signal intensity due to paramagnetic, iron-
rich, blood by products9 within the otherwise
homogeneous prostate. Blood has low signal intensity
on T2-weighted images, and can either mimic cancer
and/or lead to an inaccurate estimate of its volume4
(Figure-3).
Extra capsular extension (ECE) / Seminal
Vesicle (SV) involvement
The criteria for extra-capsular extension include
asymmetry, bulge of prostate contour, thickening of
neuro-vascular bundle(s), capsular enhancement and
breach, tumour signal in peri-prostatic fat and
obliteration of recto-prostatic angle.4,10,11 On T2WI,
these findings provide a specificity of more than 90%.
The SVs are seen as elongated fluid-filled structures
with thin septae with low signal intensity on T1-
weighted (T1W) images and high signal intensity on
T2W images.12 Combination of tumour at prostate base
extending beyond the capsule and low signal intensity
within SV in the background of high signal fluid on T2-
weighted images are highly predictive of SV invasion.13
The reported sensitivity of MRI scan for the detection of
extra capsular extension is 13-95% with specificity
ranging from 49-97%.14-16
Diffusion-weighted imaging (DWI)
Diffusion-weighted MRI uses principle of Brownian
motion of water molecules in tissues.17,18 It has
advantage of short acquisition time, improved
specificity and no requirement for any specialised
hardware.19
The rate of diffusion of water in soft tissues is lower than
in free solution and is described by the apparent
diffusion coefficient (ADC), which correlates inversely
with tissue cellularity.20 Increased cellularity and loss of
ductal morphology result in restriction of water
diffusion in prostate cancer with corresponding low
signal intensity in ADC Values.20
ADC maps can be calculated on DWI thus enabling
qualitative and quantitative assessment of the
aggressiveness of prostate cancer.6 The ADC values for
malignant tissue are commonly lower than those of
normal gland as well as benign prostatic hyperplasia
(BPH) nodules21-23 (Figure-4).
Limitations
DWI has low spatial resolution and hence lower
accuracy in the assessment of extra-capsular
extension.24 Benign conditions such as prostatitis,
compact fibro muscular stroma seen in BPH25 and organ
motion26 can also lower the ADC and hence give false
positive results. Well-differentiated tumours with
predominantly glandular components can lead to false
negative results.27
Dynamic contrast-enhanced MRI (DCE)
This imaging sequence relies on tumour neo-
angiogenesis.4 Administration of gadolinium-based
contrast is done for enhancing tumour vascularity.3
Early nodular enhancement before the rest of prostate
and early washout of signal intensity is characteristic of
prostate cancer.3
The data generated by DCE MRI is assessed in 3 ways,
i.e. qualitatively, semi-quantitatively and
quantitatively. The former way is applied in routine
clinical practice.4,28 Intensity-time curves are
generated to evaluate time to peak, maximum uptake
slope, peak enhancement and washout rates. The
quantitative approach uses more sophisticated
pharmacokinetic parameters to describe tissue
vascularisation such as mean transit time, blood flow
and permeability surface area.4,29 Jackson et al.30
showed that the sensitivity and specificity of DCE-MRI
(50% and 85%, respectively) is higher than that of T2W
imaging (21% and 81%, respectively).
Limitations
The limiting factors in DCE-MRI are motion and biopsy
artefacts. The rectal motion and patient movements
may lead to noisy curves and distorted low quality
images, therefore, bowel preparation with enema and
anti-peristaltic agents are recommended to overcome
these pitfalls.31
MR Spectroscopy Imaging (MRSI)
MRSI depicts the metabolic profile of the prostatic
tissue.4 Neoplastic proliferation leads to increased
phospholipid cell membrane turnover with resultant
difference in concentration of chemical metabolites.3
This study enables to show lower levels of citrate
(marker of benign tissue) and higher levels of choline
(marker of malignant tissue) from volumes of interest
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(voxels) that encompass prostate cancer.4
MRSI not only detects cancer but also provides
information about the lesion aggressiveness (Gleason
scoring).32 This approach can be used to evaluate the
"metabolic atrophy" after treatment and for the
detection of recurrence after radiation therapy.33 A
sensitivity and specificity as high as 95% and 91%,
respectively, has been reported for MRSI in conjunction
with endo-rectal MRI.34
Limitations
The interpretation of MRSI is challenging. The spatial
resolution is poor and therefore this study is unable to
depict the peri-prostatic area and accurate staging
information.35 It needs additional software for
interpreting the data adding to time and cost.36
MRI-guided prostate biopsy
Contrary to standard set of TRUS-guided prostate
biopsies, MRI-guided prostate biopsy targets only
area(s) considered to be suspicious, hence resulting in
improved accuracy in prostate cancer detection and
localisation, especially for the lesions that are not
routinely targeted on TRUS-guided biopsies such as
anterior tumours.37,38 MRI scan also helps in localising
the site of tumour recurrence after definitive
treatment.39
Role of MRI in planning surgery and follow-
up (surveillance and recurrence)
A safe and effective operation can be guided by
information from MRI imaging leading to oncological
clearance while preserving the peri-prostatic tissues
important for recovery of urinary and sexual function.3
MRI also helps to predict the intra-operative blood
loss. A positive correlation was observed b/w
prominence of apical peri-prostatic veins and
associated blood loss.40
Moreover, mpMRI can also predict functional
outcome after surgery. The length of membranous
urethra on coronal endo-rectal MR image is an
important predictor for urinary incontinence.41
Patients with longer than average (14mm)
membranous urethra experience more rapid return
to complete continence.
MpMRI is helpful in patients with biochemical
recurrence (rising PSA value) without any palpable
tumour in prostatic fossa. The sensitivity and specificity
of endo-rectal MRI to evaluate local recurrence (peri-
anastomotic and retro-vesical region) after
prostatectomy was reported to be 91% and 45%.42
MRI-guided focal therapies
Cryoablation and high-intensity focused ultrasound
(HIFU) are the two contemporary treatment modalities
used as focal therapy. MR-guided targeted focal and
regional therapies are increasingly used for localised
primary (native) and recurrent prostate cancer as well as
for monitoring the effectiveness of these treatments.43
Recently, pre-clinical and phase 1 trials have also
reported real-time MR-guided focal laser ablation
(FLA).44
Reporting and communication of mp-MRI
data (prostate imaging reporting and data
system (PI-RADS) classification)
European Society of Urogenital Radiology (ESUR)
prostate MR guidelines of 2012 recommend structured
reporting system for mp-MRI data, including the
following set of information:6
A) PI-RADS score (probability of cancer risk and its
aggression) 
B) Location and probability of extra-prostatic disease
C) Pertinent incidental findings.
Individual lesion(s) should be given a PI-RADS score on
a five-point scale from 1-5, with a score of "1" denoting
that clinically significant disease was highly unlikely to
be present and a score of "5" denoting that clinically
significant disease was highly likely to be present.45
Grey A.D. et al.46 found PI-RADS system to be a very
good predictor for trans-perineal prostate biopsy
outcome.
Conclusion
Mp-MRI is a rapidly evolving and useful tool for the
diagnosis, localisation and staging of prostate cancer
and to facilitate the targeted therapies. It has the
potential for reduction of unnecessary biopsies and
provides a rapid and accurate diagnosis for both native
and recurrent tumours. It should become an integral
part of prostate cancer risk assessment.
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